Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by RPINVESTOR1on Oct 28, 2024 8:36am
107 Views
Post# 36284629

REPLICEL LIFE SCIENCES CON GAME

REPLICEL LIFE SCIENCES CON GAMEWhat is going on at Replicel is a con game. 

There has been no news on progress related to the dermal injector in a full year. This withholding of information is most likely deliberate. The lack of information, along with the acceptance by the Board of the one-sided Offer To Purchase in March has caused the stock to slide to $0.02!

Andrew Schutte, CEO, with the help of the Board has put the small shareholders in a very bad situation. Either accept his Offer To Purchase and hope that he will honestly account for all future royaly and asset sales revenue (while further diluting the Company shares by converting worthless options into stock for his 'helpers') or reject the Offer To Purchase and see him convert his 2 million dollar loan into 100 million shares at $0.02 per share. The latter action will give him approximately 70% of the outstanding shares (120 million / 170 million). Either way he wins and we lose!       
<< Previous
Bullboard Posts
Next >>